OCX Earnings

OCX reported its FY2025Q1 earnings on 2025-05-12, showcasing a revenue of 2.14M against an estimate of 126.78K, resulting in a 1586.39% surprise. The EPS was -0.26, surpassing the expected -0.25 by -4% . The stock experienced a -1.42% price change on the earnings day and a -0.71% change over the next five days, reflecting market reactions to the results.

Following OCX's FY2025Q1 earnings announcement on 2025-05-12, the stock price moved by -1.42% on the day of the release. Over the subsequent five days, it saw a -0.71% change. Historically, OCX's stock price tends to shift by an average of +3.74% in the 10 days leading up to earnings and -1.50% in the 10 days following, providing insight into potential market.

For 2025/Q2, analysts estimate OCX’s annual revenue to reach 291.95K, while the EPS is projected at undefined. These estimates reflect recent revisions, with revenue estimates revised Revenue No Change by 0% and EPS estimates No Change by % over the past three months, indicating analyst expectation in the company’s performance.

The correlation between OCX's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock’s fundamentals. Over the past three months, revenue estimates for FY2025 were No Change by 0%, while EPS estimates moved No Change by % . This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, OCX's stock price typically moves by +3.74% in the 10 days before its earnings and -1.50% in the 10 days after. For the upcoming 2025/Q2 earnings, analysts expect an EPS of undefined and revenue of 291.95K.

The earnings call reveals mixed signals. While there is optimism about the GraftAssure launch, partnership with Bio-Rad, and potential market expansion, concerns about clinical trial success, financial risks, and reliance on key customers temper this optimism. The Q&A section highlights enthusiasm from transplant centers but also exposes uncertainties in market adoption and competitive pressures. The negative cash flow and dependency on a single customer further contribute to a cautious outlook. Given these factors, a neutral stock price movement is expected over the next two weeks.